Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE vs DELCOBESE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dexbrompheniramine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin by blocking the serotonin transporter (SERT). Additionally, it has a unique property of acting as an agonist at the 5-HT2C receptor, which may contribute to its anorectic effects.
Relief of symptoms associated with seasonal or perennial allergic rhinitis,Relief of nasal congestion,Symptomatic relief of upper respiratory tract infections
Chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia)
1 tablet (each containing dexchlorpheniramine maleate 2 mg/pseudoephedrine sulfate 120 mg) orally every 12 hours; maximum 2 tablets per day.
Initial dose: 0.5 mg subcutaneously once weekly for 4 weeks, then increase to 1 mg once weekly for 4 weeks, then maintain at 2 mg once weekly. Titrate based on glycemic control up to 2 mg weekly.
Dexbrompheniramine: terminal elimination half-life is approximately 12-25 hours in adults. Pseudophedrine: terminal elimination half-life is about 5-8 hours in adults with normal renal function; it is prolonged in patients with renal impairment.
12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours with Cr Cl <30 m L/min).
Dexbrompheniramine is primarily metabolized by CYP3A4 and CYP2D6. Pseudoephedrine is partially metabolized by N-demethylation and oxidative deamination, with about 43-96% excreted unchanged in urine.
Primarily metabolized by cytochrome P450 (CYP) 2D6 with minor contributions from CYP3A4 and CYP2C19. Active metabolite N-desmethyl lorcaserin is formed via CYP2D6.
Dexbrompheniramine and its metabolites are primarily excreted renally (approximately 80-85% of a dose as unchanged drug and metabolites). Pseudophedrine is largely excreted unchanged in urine (70-90%) via glomerular filtration and tubular secretion; the remainder is hepatically metabolized. Biliary/fecal elimination is minimal (<5%).
Primarily renal (60-70% unchanged) with 20-30% fecal via biliary elimination; less than 5% metabolized.
Dexbrompheniramine: approximately 90% bound to plasma proteins. Pseudophedrine: negligible protein binding (<10%).
95% bound to albumin and alpha-1-acid glycoprotein.
Dexbrompheniramine: Vd is approximately 3-5 L/kg, indicating extensive tissue distribution. Pseudophedrine: Vd is approximately 2.5-3.5 L/kg.
0.3-0.4 L/kg; indicates moderate distribution to extracellular fluid and well-perfused tissues.
Both components are well absorbed orally. Dexbrompheniramine: oral bioavailability is approximately 60-80%. Pseudophedrine: oral bioavailability is about 90-100%.
Oral: 40-50% (first-pass effect); Subcutaneous: 70-80%; IV: 100%.
GFR 30-50 m L/min: extend interval to every 12-24 hours; GFR <30 m L/min: contraindicated due to risk of accumulation.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m2). Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73 m2) or end-stage renal disease.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: contraindicated.
No dose adjustment required for mild hepatic impairment (Child-Pugh class A). Not recommended for moderate or severe hepatic impairment (Child-Pugh class B or C) due to lack of data.
Not recommended for children under 12 years; for ages 12+: same as adult dosing.
Not approved for use in pediatric patients under 18 years of age. Safety and efficacy have not been established.
Start at lowest effective dose (e.g., 1 tablet daily) due to increased sensitivity to anticholinergic effects and risk of confusion; monitor for urinary retention and hypertension.
No specific dose adjustment required; initiate at 0.5 mg subcutaneously once weekly and titrate cautiously due to potential for renal function decline and increased sensitivity. Monitor renal function and consider dose reduction if e GFR declines.
None.
WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS - Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. Monitor for worsening and emergence of suicidal thoughts and behaviors. DELCOBESE is not approved for use in pediatric patients.
Cardiovascular effects: hypertension, palpitations, arrhythmias; use cautiously in cardiovascular disease,CNS stimulation: nervousness, dizziness, insomnia; avoid in severe hypertension or coronary artery disease,Anticholinergic effects: urinary retention, blurred vision; caution in glaucoma or prostatic hypertrophy,Drug interactions: MAO inhibitors, sympathomimetics, antihypertensives
Risk of serotonin syndrome or neuroleptic malignant syndrome when coadministered with other serotonergic drugs. Potential for pulmonary hypertension. Monitor for valvular heart disease (5-HT2B receptor agonist activity). Caution in patients with renal impairment (e GFR <30 m L/min). Avoid in pregnancy (potential for fetal harm).
Hypersensitivity to any component,Severe hypertension or coronary artery disease,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation,Narrow-angle glaucoma,Urinary retention,Severe hepatic or renal impairment
Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI. Known hypersensitivity to DELCOBESE or any component. Severe renal impairment (e GFR <30 m L/min) or end-stage renal disease. History of pulmonary hypertension. Pregnancy.
Avoid high-tyramine foods (e.g., aged cheese, cured meats, fermented products) if taking MAOIs concurrently. Pseudoephedrine's pressor effect may be enhanced by caffeine; limit caffeinated beverages.
Avoid grapefruit and grapefruit juice which inhibits CYP3A4 metabolism increasing DELCOBESE levels. Avoid high-fat meals as they increase absorption and risk of adverse effects. Limit alcohol to no more than 1 drink per day due to additive CNS depression. Ensure adequate hydration to prevent constipation.
First trimester: Avoid; limited human data, but theoretical risk of antihistamine-related malformations. Second and third trimesters: Caution; pseudoephedrine may reduce uterine blood flow and cause fetal tachycardia.
DELCOBESE is contraindicated in pregnancy. First trimester exposure is associated with increased risk of major congenital malformations, particularly neural tube defects, cardiac anomalies, and cleft palate. Second and third trimester exposure can cause fetal growth restriction, oligohydramnios, and neonatal renal impairment. There is a dose-dependent risk of pregnancy loss.
Probable compatibility (American Academy of Pediatrics rating). Pseudoephedrine is excreted into breast milk in small amounts (M/P ratio ~3.3); may cause irritability and sleep disruption in infants. Dexbrompheniramine may suppress lactation. Consider using alternatives with lower risk.
Excretion into breast milk is unknown; due to potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during therapy and for at least 1 week after the last dose. No M/P ratio data available.
No specific adjustments recommended. However, decreased gastrointestinal motility and increased plasma volume may alter absorption and distribution. Monitor clinical response.
Do not use in pregnancy. No dosing adjustment recommendations exist as the drug is contraindicated. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered metabolism) are not applicable.
Dexbrompheniramine is an alkylamine antihistamine with sedative effects; pseudoephedrine is a sympathomimetic decongestant. Avoid in severe hypertension, coronary artery disease, or MAOI use. Monitor for CNS stimulation (insomnia, nervousness) from pseudoephedrine. Antihistamines may exacerbate urinary retention in BPH or narrow-angle glaucoma. Combination therapy is common in OTC cold products.
DELCOBESE is a novel synthetic cannabinoid receptor antagonist/inverse agonist (CB1R) approved for weight management. Monitor for psychiatric adverse effects (depression, suicidal ideation) especially during first 3 months. Avoid in patients with history of seizures due to lowered seizure threshold. Titrate dose slowly: start at 5 mg BID, increase to 10 mg BID after 4 weeks if tolerated. Discontinue if no 5% weight loss at 12 weeks. Use contraception in women of childbearing potential due to teratogenicity. Check liver function tests monthly for first 6 months due to rare hepatotoxicity.
Take with food or milk to reduce stomach upset.,Avoid alcohol and other CNS depressants due to additive sedation.,Do not crush or chew extended-release formulations.,Discontinue and consult prescriber if palpitations, dizziness, or tremor occur.,Not recommended for children under 6 years without prescriber approval.,Use caution when driving or operating machinery until response is known.
Take exactly as prescribed; do not exceed 20 mg per day.,May cause dizziness or drowsiness; avoid driving until you know how this drug affects you.,Report any new or worsening depression, anxiety, or thoughts of self-harm immediately.,Use effective contraception during treatment and for 1 month after stopping.,Avoid alcohol and grapefruit juice as they may increase side effects.,Inform your doctor if you have a history of seizures or liver disease.,Do not stop suddenly; taper under medical supervision to avoid withdrawal symptoms.,Maintain a reduced-calorie diet and exercise program for best results.
"Coadministration of phenytoin and dexbrompheniramine may increase the risk of central nervous system (CNS) depression, leading to excessive sedation, dizziness, and impaired psychomotor function. Phenytoin, a sodium channel blocker used for seizure control, and dexbrompheniramine, a first-generation antihistamine with strong anticholinergic and sedative properties, synergistically depress CNS activity. This interaction can result in additive sedation, potentially compromising patient safety, especially in activities requiring alertness."
"Dexbrompheniramine, a first-generation antihistamine with anticholinergic and sedative properties, when co-administered with guanfacine, an alpha-2 adrenergic agonist used for hypertension or ADHD, can result in additive central nervous system depression. This may lead to enhanced sedation, dizziness, impaired cognitive function, and increased risk of falls, particularly in older adults or those with compromised liver function."
"Quazepam, a benzodiazepine, and dexbrompheniramine, a first-generation antihistamine, both exhibit central nervous system (CNS) depressant effects. Their combined use can lead to additive sedation, psychomotor impairment, and respiratory depression, increasing the risk of falls, cognitive dysfunction, and excessive drowsiness. This interaction is particularly concerning in elderly patients or those with compromised respiratory function."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE vs DELCOBESE, answered by our medical review team.
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE is a Sympathomimetic that works by Dexbrompheniramine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. DELCOBESE is a Anorectic (sympathomimetic) that works by Selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin by blocking the serotonin transporter (SERT). Additionally, it has a unique property of acting as an agonist at the 5-HT2C receptor, which may contribute to its anorectic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE and DELCOBESE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE is: 1 tablet (each containing dexchlorpheniramine maleate 2 mg/pseudoephedrine sulfate 120 mg) orally every 12 hours; maximum 2 tablets per day.. The standard adult dose of DELCOBESE is: Initial dose: 0.5 mg subcutaneously once weekly for 4 weeks, then increase to 1 mg once weekly for 4 weeks, then maintain at 2 mg once weekly. Titrate based on glycemic control up to 2 mg weekly.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE and DELCOBESE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE is classified as Category A/B. First trimester: Avoid; limited human data, but theoretical risk of antihistamine-related malformations. Second and third trimesters: Caution; pseudoephedrine may reduce uterine bl. DELCOBESE is classified as Category C. DELCOBESE is contraindicated in pregnancy. First trimester exposure is associated with increased risk of major congenital malformations, particularly neural tube defects, cardiac a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.